Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. Ascletis Pharma Inc.
  6. News
  7. Summary
    1672   KYG0520K1094

ASCLETIS PHARMA INC.

(1672)
  Report
Delayed Hong Kong Stock Exchange  -  04:08 2022-09-30 am EDT
2.750 HKD   +0.73%
09/28Ascletis Pharma H1 Loss Down by 20.6%
MT
09/28Ascletis Pharma Doses First Patient in Phase 2B Trial of Hepatitis B Treatment
MT
09/27Ascletis Announces Dosing of the First Patient in the Phase IIb Expansion Cohort of ASC22 (Envafolimab) for Chronic Hepatitis B Functional Cure
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Chinese Regulator Accepts Ascletis Pharma's New Drug Application for Oral Inhibitor

08/03/2022 | 08:36pm EDT


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
ASCLETIS PHARMA INC. 0.73% 2.75 Delayed Quote.-16.41%
HKG LIMITED -3.41% 17 End-of-day quote.-11.30%
All news about ASCLETIS PHARMA INC.
09/28Ascletis Pharma H1 Loss Down by 20.6%
MT
09/28Ascletis Pharma Doses First Patient in Phase 2B Trial of Hepatitis B Treatment
MT
09/27Ascletis Announces Dosing of the First Patient in the Phase IIb Expansion Cohort of ASC..
CI
09/19Ascletis Pharma Unit Terminates Promotion Services Deal with Shanghai Roche Pharmaceuti..
MT
09/16Ascletis Pharma Inc. and Shanghai Roche Pharmaceutical Ltd. Announce Signing of an Adde..
CI
09/15Shanghai Public Health Clinical Center Completed Patient Enrollment in Clinical Study o..
PR
09/15Ascletis Pharma Inc. Announces Clinical Study of PD-L1 antibody ASC22
CI
08/22China Approves New Drug Application for Ascletis Pharma's COVID-19 Oral Treatment
MT
08/21Ascletis Announces IND Approval of Oral RdRp Inhibitor ASC10 for COVID-19 by China NMPA
PR
08/21Ascletis Announces IND Approval of Oral RdRp Inhibitor ASC10 for COVID-19 by China NMPA
CI
More news
Financials
Sales 2022 104 M 14,7 M 14,7 M
Net income 2022 -233 M -32,8 M -32,8 M
Net cash 2022 2 340 M 329 M 329 M
P/E ratio 2022 -11,9x
Yield 2022 -
Capitalization 2 709 M 381 M 381 M
EV / Sales 2022 3,54x
EV / Sales 2023 2,04x
Nbr of Employees 315
Free-Float 33,2%
Chart ASCLETIS PHARMA INC.
Duration : Period :
Ascletis Pharma Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASCLETIS PHARMA INC.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 3
Last Close Price 2,49 CNY
Average target price 2,10 CNY
Spread / Average Target -15,8%
EPS Revisions
Managers and Directors
Jinzi J. Wu Chairman & Chief Executive Officer
Zhengqing Li Chief Medical Officer
Handan He Chief Scientific Officer
Yan Yuemei Senior VP-Clinical Development & Operations
Jiong Gu Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
ASCLETIS PHARMA INC.-16.41%381
CSL LIMITED-1.96%88 546
SAMSUNG BIOLOGICS CO.,LTD.-10.63%39 998
BIOGEN INC.11.29%38 745
WUXI BIOLOGICS (CAYMAN) INC.-48.78%25 758
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.-30.63%19 438